Effect of glucagon-like peptide-1 receptor agonist on cardiovascular risk markers in patients with type 2 diabetes mellitus
- Authors: Mkrtumyan A.M1, Podachina S.V1, Sviridova M.I2
-
Affiliations:
- FSBEI HE "MSMSU n.a. A.I. Evdokimov" of RMH
- Treatment and Rehabilitation Center of Ministry of Economic Development of the Russian Federation
- Issue: No 16 (2016)
- Pages: 56-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289269
- ID: 289269
Cite item
Open Access
Access granted
Abstract
The effect of the glucagon-like peptide-1 receptor agonist, exenatide, on the dynamics of cardiovascular risk markers, glucose triad indicators, lipid metabolism, body weight, waist circumference (WC) and body mass index (BMI) in patients with type 2 diabetes mellitus (DM2) was evaluated. The study included 70 patients; main group consisted of 50 patients who received exenatide for 6 months according to classic treatment regimen. Twenty patients were comparison group and received conventional glucose-lowering therapy. Prior to the beginning and at the end of the study, markers of cardiovascular risk were assessed in both groups: C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha), integrated indicator of the status of carbohydrate metabolism, glycated hemoglobin (HbA1c), lipid profile, body weight, WC, and BMI. At the end of the study, there was a significant decrease in CRP levels (p<0.001) and a trend towards reduction in TNF-α levels (p<0.1) in the exenatide group versus the comparison group. Significant reduction in low-density lipoprotein cholesterol, increase in high-density lipoprotein cholesterol levels, and reduction of atherogenic index were observed in exenatide group. Also, highly significant (compared to the comparison group) decrease in body weight, BMI, HbA1c levels and WC were noted in main group. Thus, exenatide was effective not only as prandial regulator, but also as a preparation with pleiotropic effects having beneficial influence on cardiovascular risk markers in DM2 patients, which suggests the presence of cardioprotective effect of this drug.
Full Text
About the authors
A. M Mkrtumyan
FSBEI HE "MSMSU n.a. A.I. Evdokimov" of RMH
Email: vagrashot@mail.ru
MD, Prof., Head of the Department of Endocrinology and Diabetology
S. V Podachina
FSBEI HE "MSMSU n.a. A.I. Evdokimov" of RMHDepartment of Endocrinology and Diabetology
M. I Sviridova
Treatment and Rehabilitation Center of Ministry of Economic Development of the Russian Federation
References
- Atlas ID, 7th ed, 2015
- Материалы XII Московского городского съезда эндокринологов «Эндокринология столицы-2016». М.а, 2016.
- Маслова О.В., Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Diabetes Mellitus. 2011;3:6-12.
- Engelgau M.E., Narayan K.M.V., Herman W.H. Screening for type 2 diabetes. Diabetes Care. 2000;23:1563-80.
- Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352(9131):837-53.
- Мамедов М.Н., Марданов Б.У., Дудинская Е.Н. Сердечная недостаточность у больных сахарным диабетом: диагностика, лечение, профилактика. М.: Фонд «Кардиопрогресс», 2015. С. 7.
- Zourelias L., Stolarski C., Shen Y.T., Shannon R.P Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955-61.
- Nicolaidis L.A., Mankad S., Sokos G.G., Miske G., Shan A., Elahi D., Shannon R.P Effects of Glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8): 962-65.
- American Diabetes Association; National Hert, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Disease; American Heart Assotiation. Diabetes Mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132-33.
- Zimmet P., Bloomgarden Z. How do we gauge the success of treatment of diabetes? J. Diabetes. 2012;4(3):193-34.
- Дедов И.И., Александров А.А., Кухаренко С.С. и др. Ишемическая болезнь сердца и сахарный диабет: алгоритмы диагностики, профилактики и лечения. Пособие для врачей. М.: Изд-во Берег, 2007. С. 4-6.
- Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Мкртумян А.М., Петунина Н.А., Сухарева О.Ю. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД2. 2011.
- Norris S.L., Lee N., Thakurta S., Chan B.K. Exenatide efficacy and safety: a systematic review. Diabet. Med. 2009;26(9):837-46.
- Викулова О.К., Шестакова М.В. Новые показания к терапии эксенатидом у больных с сахарным диабетом 2 типа и ожирением. Сахарный диабет. 2010;3:98-101.
- Gutzwiller J., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., Beglinger C. Glucagon-like peptide-1 promotes safiety and reduced food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 1999;276:665-73.
- Bunck M.C., Diamant M., Eliasson B., Corner A., Shaginian R.M., Heine R.J., Taskinen M.R., Yki-Jarvinen H., Smith U. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734-37.
- Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factor non-insulin-depend diabetes mellitus. Lancet. 1997;350(Suppl.1):20-3.
- Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 2008;24(1):275-86.
Supplementary files
